Medivir - New Data on MIV-818 Will be Presented at EASL's International Liver Congress™ 2017

STOCKHOLM, April 06, 2016 /PRNewswire/ --

Medivir AB (Nasdaq Stockholm: MVIR) today informs that preclinical data on MIV-818 will be presented by Medivir at The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April. The poster presentation, abstract SAT-123, is entitled "Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers" and will include data on the anticancer activity and pharmacokinetic profile of MIV-818.

Details of all presentations for The International Liver Congress™ 2017 are available at the website: http://www.easl.eu/.

For further information, please contact:

Richard Bethell,
CSO Medivir AB,
Mobile +46 (0)72-704 3211

Ola Burmark,
CFO Medivir AB,
Mobile: +46 (0) 725-480-580

About Medivir

Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medivir/r/new-data-on-miv-818-will-be-presented-at-easl-s-international-liver-congress--2017,c2233897

The following files are available for download:

SOURCE Medivir